ESPN 50th Annual Meeting

ESPN 2017

Impact Of Recombinant Human Erythropoietin Treatment On Left Ventricular mass and cardiac function in Patients With End Stage Renal Disease On Haemodialysis
MONA ZAHRANE 1 naglaa abdel rahman 1 soha emam 1


Objective:of this work was to demonstrate the effect of rHu EPO therapy on LVH and LV systolic function in patients with end stage kidney disease.

Material and methods:

Thirty two patients were enrolled in this study, 14 females and 18 males. Their age ranged from 5 to 17 years along with 15 age and sex matched healthy subjects as controls. The inclusion criteria were; the presence of renal anemia , adequate serum iron status with serum ferritin level of 100 ng/ml or more and a transferrin saturation of >20%, normotension or controlled hypertension and no history of valid heart disease or other systemic illness. We analyzed the laboratory and echocardiographic data before starting EPO treatment and after treatment in period of follow up ranged between 4 and 9 months with a mean of 5.8+/-1.5 months.


Hb level increased from 8.5+/-1.87 to 9.3+/-1.7 gm/dl, Hct level increased from 25.78+/-6.59% to 28.88+/-5.5%, LVMI showd reduction from 108.8+/-41.97 to 97.13+/-43.9 g/m2 , SV decreased from 59.58+/-21.17 to 53.9+/-18.49 ml and finally CO decreased from 5.74+/-2.2 to 5+/-1.5 L/minute. No significant change was detected regarding the HR, EDV, &ESV. LV systolic function was normal at the start of the work and remained so in the follow up examination.


We concluded that in patients with ESRD on chronic hemodialysis, LVH regression can be obtained after partial correction of anemia with rHu EPO which can be also associated with reduction of the high CO encountered in these cases. Weather this regression would improve outcome in haemodialysis patients remain to be established.